ABL1 and acute lymphoblastic leukemia: To date, although NGS has been widely used to detect ABL1 KD mutations in BCR::ABL1‐positive ALL patients, few studies have focused on the clinical characteristics and TKI susceptibility of mutations other than ABL1 KD‐resistant ones [14, 15, 16, 17].